Artificial Lipid Biomembranes for Full‐Length SARS‐CoV‐2 Receptor

Abstract The angiotensin‐converting enzyme 2 (ACE2), as a functional receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is essential for assessing potential hosts and treatments. However, many studies are based on its truncated version but not full‐length structure. Indeed, a single transmembrane (TM) helix presents in the full‐length ACE2, influencing its interaction with SARS‐CoV‐2. Therefore, synthesis of the full‐length ACE2 is an urgent requirement. Here, cell‐free membrane protein synthesis systems (CFMPSs) are constructed for full‐length membrane proteins. MscL is screened as a model among ten membrane proteins based on their expression and solubility. Next, CFMPSs are constructed and optimized based on natural vesicles, vesicles with four membrane proteins removed or two chaperonins added, and 37 types of nanodiscs. They all increase membrane protein solubility to over 50%. Finally, the full‐length ACE2 of 21 species are successfully expressed with yields between 0.4 and 0.9 mg mL −1 . The definite functional differences from the truncated version suggest that the TM region affects ACE2's structure and function. CFMPSs can be extended to more membrane proteins, paving the way for further applications.